Mirtazapin Hexal (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Hexal, is a tetracyclic antidepressant presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a tetracyclic antidepressant used primarily in depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves functional outcomes. - Depressive episodes in bipolar disorder (off‑label): may alleviate the depressive phase when other options are limited. - Anxiety symptoms associated with depression (off‑label): can help lower concurrent anxiety and improve sleep quality.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts or behavior, especially early in treatment - Severe hypersensitivity reactions (rash, angioedema) - Serotonin syndrome when combined with other serotonergic agents - Cardiac arrhythmias (QT prolongation) in susceptible individuals - Hepatotoxicity (rare liver injury).

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Monitor weight: watch for significant gain and metabolic changes. - Assess suicidal ideation: especially during the first weeks of treatment. - Evaluate liver function: adjust if hepatic impairment is present. - Use caution in the elderly: increased sensitivity to sedation and orthostatic hypotension. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may precipitate serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Antihypertensive drugs: additive hypotensive effect may occur. - Alcohol: can worsen sedation and impair psychomotor performance.